Smoothie King introduced a GLP-1 Support Menu designed for consumers using weight-loss medications
Combining your genetic insights with your provider's clinical assessmentBMI, metabolic markers, cardiovascular health, and medication historycreates a more complete picture for personalized treatment planning
If you want results grounded in evidence not hype begin your consultation today at Medvi.org .
Second-generation compounds like semaglutide improved on pharmacokinetic profiles, enabling once-weekly dosing and stronger clinical efficacy
Theyre also impactful because some IVF clinics have BMI restrictions, often because providers can't safely do IVF or put patients to sleep for egg retrieval if their BMI is over 45
FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available
